More about

Drug-Eluting Stent

News
July 13, 2023
2 min read
Save

Prognosis after PCI affected by interaction of chronic kidney disease, diabetes in women

Concomitant chronic kidney disease and diabetes was prognostic of all-cause death and MI within 3 years among women undergoing drug-eluting stent implantation, according to new data.

News
July 11, 2023
2 min read
Save

FDA: No excess mortality risk with paclitaxel-coated devices for PAD

Warnings about excess mortality risk with paclitaxel-coated devices to treat peripheral artery disease are “no longer supported,” based on a updated review of relevant trial data, according to an FDA announcement.

News
May 19, 2023
2 min read
Save

5-year data show titanium-nitride-oxide coated stents may be safer than DES

In patients with ACS, there were no differences in 5-year risk for cardiac death, MI or target lesion revascularization for those who received titanium-nitride-oxide-coated stents vs. biodegradable polymer drug-eluting stent, data show.

News
May 18, 2023
2 min read
Save

Similar performance, outcomes with drug-eluting adaptable implant vs. DES: BIOADAPTOR

A drug-eluting coronary implant adaptable to vessel physiology with uncaging elements was safe and effective compared with a contemporary drug-eluting stent, demonstrating superior restoration of vessel motion and function, data show.

News
May 18, 2023
1 min read
Save

HOST-IDEA

Comparing single antiplatelet therapy after 3-month DAPT with 12-month DAPT after PCI with third-generation DES with the thinnest struts.

News
May 17, 2023
3 min read
Save

Long-term outcomes mixed for bioresorbable scaffold vs. metallic stent: ABSORB IV

Compared with metallic drug-eluting stents, a first-generation everolimus-eluting bioresorbable vascular scaffold had similar 5-year rates of death, patient-oriented composite events, angina recurrence and quality of life, data show.

News
March 21, 2023
2 min read
Save

3-month DAPT noninferior to 12-month after PCI using third-generation stents

NEW ORLEANS — An all-comers trial excluding patients with STEMI showed that after PCI, 3-month dual antiplatelet therapy was noninferior to 12-month DAPT for the composite outcome of net adverse clinical events, a speaker reported.

News
January 26, 2023
1 min read
Save

Head-to-head DES trial shows differing outcomes for adults with diabetes

Among adults with diabetes who underwent PCI, rates of target lesion failure were similar for two drug-eluting stents, though net adverse clinical events varied between arms and differed for people taking insulin, data show.

News
November 10, 2022
2 min read
Save

OPTION: Feasible to replace aspirin with indobufen in DAPT after PCI

CHICAGO — In patients who had PCI with a drug-eluting stent, dual antiplatelet therapy with indobufen plus clopidogrel was noninferior to DAPT with aspirin plus clopidogrel, according to the results of the OPTION trial.

News
November 07, 2022
10 min watch
Save

VIDEO: Takeaways from AHA 2022 with B. Hadley Wilson, MD, FACC

CHICAGO — In this Healio exclusive, B. Hadley Wilson, MD, FACC, provides his perspective on several late-breaking clinical trials presented at the American Heart Association Scientific Sessions.

View more